|
|
Volumn 104, Issue 6, 2012, Pages 434-439
|
|
Future of immunotherapy drug combinations and biomarkers.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
CANCER VACCINE;
CTAG1B PROTEIN, HUMAN;
INDOLE DERIVATIVE;
IPILIMUMAB;
MEMBRANE PROTEIN;
MONOCLONAL ANTIBODY;
SIPULEUCEL T;
SULFONAMIDE;
TISSUE EXTRACT;
TUMOR ANTIGEN;
VEMURAFENIB;
CLINICAL TRIAL (TOPIC);
DRUG COMBINATION;
DRUG EFFECT;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
METHODOLOGY;
NOTE;
T LYMPHOCYTE;
UNITED STATES;
ANTIBODIES, MONOCLONAL;
ANTIGENS, NEOPLASM;
BIOLOGICAL MARKERS;
CANCER VACCINES;
CLINICAL TRIALS AS TOPIC;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOTHERAPY;
INDOLES;
MEMBRANE PROTEINS;
SULFONAMIDES;
T-LYMPHOCYTES;
TISSUE EXTRACTS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84860588910
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djs186 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
